Prosperity Consulting Group LLC Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

Prosperity Consulting Group LLC raised its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 33.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,774 shares of the company’s stock after purchasing an additional 701 shares during the quarter. Prosperity Consulting Group LLC’s holdings in Zoetis were worth $481,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in ZTS. International Assets Investment Management LLC boosted its holdings in Zoetis by 40.7% in the 4th quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock valued at $479,000 after purchasing an additional 703 shares in the last quarter. Aveo Capital Partners LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $225,000. Gryphon Financial Partners LLC lifted its position in shares of Zoetis by 11.8% during the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after acquiring an additional 322 shares during the period. Jump Financial LLC acquired a new stake in shares of Zoetis during the 4th quarter valued at approximately $339,000. Finally, Avantax Advisory Services Inc. lifted its position in shares of Zoetis by 7.4% during the 4th quarter. Avantax Advisory Services Inc. now owns 9,627 shares of the company’s stock valued at $1,900,000 after acquiring an additional 662 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.2 %

Shares of Zoetis stock opened at $191.09 on Friday. The business has a 50 day moving average price of $182.85 and a 200 day moving average price of $174.32. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The company has a market capitalization of $86.57 billion, a P/E ratio of 36.82, a P/E/G ratio of 2.92 and a beta of 0.88. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. Zoetis’s revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.41 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $200.00 price target on shares of Zoetis in a research report on Tuesday, August 27th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $217.11.

Get Our Latest Stock Report on ZTS

Zoetis Company Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.